United States: 2014 OIG Work Plan Released: Our Observations On Enforcement

Last Updated: February 24 2014
Article by Jason S. Greis

The Office of the Inspector General ("OIG") of the Department of Health and Human Services ("HHS") recently released its Work Plan for Fiscal Year 2014 (the "Work Plan").  Usually issued in October, budget pressures delayed this year's release.  The Work Plan provides an annual view into the OIG's planned areas of focus for investigation and enforcement activities in the coming year.  Below are a few interesting observations from this year's Work Plan.

  1. Provider-Based Facilities and Site of Service Billing Errors.  The OIG intends to continue its focus on provider-based facilities.  Provider-based facilities are hospital outpatient departments and are often located off-campus.  These facilities tend to be paid more than free-standing clinics for similar Medicare services in recognition of the generally higher levels of overhead and infrastructure necessary to qualify as a hospital-based facility. Unlike physician practice clinics, services at a provider-based facility are reimbursed both a technical fee (from the hospital) and professional fees (from the physician).  Past OIG reports have documented cases of incorrect billing to obtain additional monies (e.g., filing claims with a provider-based site of service for technical fees, while reporting a physician office site of service for professional fees). The OIG plans to further investigate such improper place of service billing and study differential payments between provider-based and free-standing clinics. From an enforcement perspective, the OIG appears most concerned about abusive practices resulting in improper provider-based payments. From a policy perspective, the OIG's concerns echo those articulated by MedPAC in the past – namely, that Medicare should seek to pay similar amounts for similar services. The OIG is expected to issue its report on the impact of provider-based reimbursement on Medicare later this year.  Providers operating provider-based facilities should continue to ensure that they comply with all of the Medicare provider-based rules.  In addition, hospitals may wish to consider adding site of service billing reviews to their annual compliance audits, if not already included.
  2. Compounding Pharmacy Practices.  The OIG intends to review Medicare's oversight of pharmaceutical compounding in Medicare-participating acute care hospitals and how State agencies and accrediting organizations evaluate such pharmacy services in hospitals.  Further, the OIG will examine the Medicare Administrative Contractors' (MACs') policies and procedures for reviewing and processing Part B claims for compounded drugs and assess the appropriateness of such claims.  Compounded drugs must be produced in accordance with the Federal Food, Drug and Cosmetic Act (FFDCA) in order for the compounded drugs to be eligible for coverage under Medicare Part B. 
  3. Payments for Pharmaceuticals.  The OIG intends to review the potential savings Medicare Part B might achieve if Medicare were able to participate in shared savings for 340B purchased drugs.  Currently, Medicare Part B providers who purchase drugs under the 340B program may retain the difference between the average-sales-price based payment received from Medicare and the amount the Part B provider spent purchasing the drug in the 340B program. Previous OIG studies showed that some Medicaid state agencies have developed strategies and shared in the savings of the discounts on 340B drugs and now the OIG will study whether there is the potential for Medicare to emulate the savings achieved by some Medicaid state agencies.   In a similar vein, the OIG has previously determined that Part D sponsors and State Medicaid agencies paid pharmacies roughly the same amount for brand-name drugs, however, the Medicaid rebate amounts exceeded by a substantial margin the Part D rebate amounts resulting in lower drug program costs for Medicaid.  In 2014, the OIG will compare pharmacy reimbursement and rebate amounts for a sample of brand-name drugs paid by Medicare Part D and by Medicaid.
  4. Hospital Quality and Safety.  The OIG intends to review two new subject areas regarding hospital quality of care and safety: emergency preparedness and hospital privileging. Currently, CMS's Conditions of Participation (CoPs) require hospitals to have adequate medical and nursing staff during emergencies.  Further, CMS has issued a Proposed Rule that revises CMS's CoPs to require hospitals to develop an emergency preparedness plan utilizing an all-hazards approach.  Hurricane Sandy dramatically affected multiple hospitals in the New York City area and the OIG intends to assess and describe hospital preparedness and response during Hurricane Sandy.  Specifically, the OIG will review Hurricane Sandy affected hospitals' participation in the Public Health Emergency Preparedness Cooperative Agreements program and the Hospital Preparedness Program.  Second, the OIG will determine how hospitals assess medical staff candidates prior to granting initial privileges.  The OIG intends to complete this review because robust hospital privileging programs has been found to contribute to patient safety. 
  5. Hospital Cost Control Reviews.  The OIG also intends to review contractor employee salaries charged to Medicare to determine whether contractors applied a regulatory required senior executive compensation benchmark.  A "senior executive" is defined as the top five compensated employees of each organizational segment.  The OIG aims to determine the potential cost savings if contractors were required to apply the same benchmark to all employee compensation.
  6. Review of Long-Term Care Hospital (LTCH) Interrupted Stay Payments.  The OIG will continue its investigation of readmission patterns in LTCHs to determine the extent to which Medicare has overpaid LTCHs for higher paying new stay cases when they should have instead been paid as interrupted stays.  An interrupted stay occurs when a patient is discharged from an LTCH for treatment and services that are not available at the LTCH (e.g., at a skilled nursing facility, inpatient rehabilitation facility, general acute care hospital) and is subsequently readmitted within a specific number of days.  If patients are readmitted to the LTCH after a specific number of days, the stays are billed as new admissions rather than interrupted stays and the LTCHs will receive two Medicare payments.  The OIG will also evaluate the extent to which co-located LTCHs readmit patients from the providers with which they are co-located in an effort to determine the extent to which Medicare made improper payments.  This investigation stems from CMS's acknowledged difficulty in detecting readmissions and to appropriately pay the readmissions as interrupted stays instead of as higher paying new admissions. 
  7. Ambulatory Surgical Center ("ASC") vs. HOPD Payments.  The OIG will continue its efforts to review the appropriateness of the ASC payment system (currently modeled on the hospital outpatient prospective payment system ("PPS")) compared with hospital outpatient department ("HOPD") payments.  Although the payment systems are similar, MedPAC has found that Medicare pays hospital outpatient departments (on average) 78 percent more than it pays ASCs for the performance of similar surgical services. The OIG will evaluate whether patient acuity and other factors justify divergent rates for similar services provided in the different environments.  The OIG is expected to release its report later this year.
  8. End Stage Renal Disease ("ESRD") Bundled Payments.  The OIG will continue reviewing payments for ESRD Services and drugs under its bundled PPS rate.  CMS has been implementing an ESRD PPS over a four-year transition period.  As part of the PPS rate, CMS utilizes Bureau of Labor Statistics' ("BLS") wage and price proxy data for annual updates.  Previously, the OIG questioned the accuracy of the BLS' data to measure a facility's costs in acquiring ESRD drugs.  The OIG's review of payment accuracy comes as ESRD facilities adjust to lower payments beginning in calendar year 2014.  The OIG's findings may impact future calls for ESRD payment changes. 
  9. Anesthesia Service Billing for Personally Performed Services.  The OIG continues its investigation into billing anesthesia services as personally performed by an anesthesiologist (service code "AA") in contrast with services under his or her medical direction (service code "QK").  Medicare pays for AA-coded services at a rate that can be up to double the rate for QK-coded services.  The OIG fears this incentivizes improperly billed AA services when the anesthesiologist does not actually personally perform the service.  Meanwhile, the industry hopes the report also helps to highlight certain payment ambiguities in the 20 year old service codes, including how to bill a service that begins as medically directed but ends as personally performed.
  10. Laboratory Tests Billing Under Part B.  The OIG will continue reviewing Part B clinical laboratory tests for questionable billing practices.  Medicare covers most lab tests and pays 100% of allowable charges.  Past OIG reports have suggested Medicare pays 18% to 30% more than other insurers for these tests.  Such high reimbursement may be one reason Medicare payments for lab services grew 92% between 1998 and 2008.  According to a past OIG report, paying equivalent to the lowest insurer in 2011 for 20 common tests would have saved taxpayers approximately $910 million.  In an area with growing costs and potentially recognizable savings, the OIG will likely target this area for the foreseeable future.
  11. Hospital Networks Security.  The OIG has added a new research initiative focused on hospitals' control of networked medical devices.  These devices often contain large amounts of sensitive electronic protected health information ("PHI").  One would not be surprised that the OIG is concerned in light of recent high-profile data security breaches.  This should be a signal to all health care providers (and not just hospitals) that steps should be taken to safeguard PHI. 
  12. Medicaid Dental Services.  The OIG continues to focus on Medicaid pediatric dental services.  Medicaid covers comprehensive dental care for 30 million low-income children through the program's early and periodic screening, diagnosis, and treatment program.  Past OIG reports found three out of four children had not received all of their required screenings.  The OIG plans to determine if CMS's response has been effective.  In addition, the OIG will continue investigations into inappropriate Medicaid dental billing.  Past reports found 31% of dental services "resulted in improper payments" (albeit, most were documentation errors).  Last year, Senators Baucus and Grassley released a report on a similar topic, suggesting continued interest among key policymakers to reform these Medicaid benefits.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions